GenomeDx Announces Inclusion of Decipher Genomic Testing in NCCN Guidelines for Prostate Cancer
Decipher testing recognized as standard-of-care in management of prostate cancer patients
SAN DIEGO, Feb. 22, 2018 -- (Healthcare Sales & Marketing Network) -- GenomeDx Biosciences, a leader in the field of urologic cancer genomics, today announced tha... Diagnostics, Oncology GenomeDx Biosciences, NCCN, Decipher Prostate, Prostate Cancer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Marketing | Pharmaceuticals | Prostate Cancer | Urology & Nephrology